

PRODUCT INFORMATION



5-*trans*-17-phenyl trinor Prostaglandin F_{2a} ethyl amide

Item No. 10008132

CAS Registry No.: 1163135-95-2
Formal Name: N-ethyl-9 α ,11 α ,15S-trihydroxy-17-phenyl-18,19,20-trinor-prosta-5E,13E-dien-1-amide

Synonyms: 5-*trans* Bimatoprost, 5,6-*trans*-17-phenyl trinor PGF_{2a} ethyl amide

MF: C₂₅H₃₇NO₄


FW: 415.6

Purity: ≥98%

Supplied as: A solution in methyl acetate

Storage: -20°C

Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

5-*trans*-17-phenyl trinor Prostaglandin F_{2a} (PGF_{2a}) ethyl amide is supplied as a solution in methyl acetate. To change the solvent, simply evaporate the methyl acetate under a gentle stream of nitrogen and immediately add the solvent of choice. Solvents such as ethanol, DMSO, dimethyl formamide (DMF), and acetonitrile purged with an inert gas can be used. The solubility of 5-*trans*-17-phenyl trinor PGF_{2a} ethyl amide in ethanol is approximately 30 mg/ml, approximately 25 mg/ml in DMSO and DMF, and approximately 3 mg/ml in acetonitrile.

Description

17-phenyl trinor PGF_{2a} ethyl amide is an F-series PG analog which has been approved for use as an ocular hypotensive drug.¹ 5-*trans*-17-phenyl trinor PGF_{2a} ethyl amide is an isomer of 17-phenyl trinor PGF_{2a} ethyl amide wherein the double bond between carbons 5 and 6 has been changed from *cis* (Z) to *trans* (E). The *trans* isomer of 17-phenyl trinor PGF_{2a} ethyl amide occurs as an impurity in commercial preparations of the bulk drug product. The present compound was prepared primarily as an analytical standard for detection and quantitation of this impurity. From what can be inferred from the study of other *trans* isomers of F-type PGs, the biological activity of this isomer is likely to be similar to that of the *cis* isomer. However, there are no specific published reports on the biological activity of 5-*trans*-17-phenyl trinor PGF_{2a} ethyl amide.

Reference

1. Woodward, D.F., Krauss, A.H.-P., Chen, J., *et al.* The pharmacology of Bimatoprost (Lumigan™). *Survey of Ophthalmology* **45**, S337-S345 (2001).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/23/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM